8-K: Senseonics Reports Strong Q3 Revenue, Announces 1:20 Reverse Stock Split

Senseonics Holdings, Inc. announced preliminary unaudited third-quarter 2025 revenue of $8.1 million, a 91% increase year-over-year, alongside a 1-for-20 reverse stock split effective October 17, 2025.

Summary

• Preliminary unaudited revenue for the third quarter of 2025 was $8.1 million.
• Revenue increased by 91% compared to the third quarter of 2024.
• U.S. new patient growth was approximately 160% over the prior year.
• The company achieved record quarterly new patient starts in Q3 2025, with September 2025 marking the highest monthly new patient starts in its history.
• A 1-for-20 reverse stock split will be effective at 5:00 p.m. Eastern Time on October 17, 2025.
• Post-split trading will commence at market open on October 20, 2025.
• The reverse split will reduce outstanding shares from approximately 816 million to approximately 41 million.
• Stockholders approved the reverse stock split on September 29, 2025, and the Board approved the final ratio on October 3, 2025.

Sentiment

Score: 7

Explanation: The company reported strong preliminary revenue growth and significant new patient acquisition, indicating positive operational momentum for its Eversense CGM system. However, the announcement of a 1-for-20 reverse stock split, while approved by shareholders, often carries a negative market perception and is typically done to meet listing requirements or improve stock attractiveness, which introduces a degree of uncertainty.

Positives

• Preliminary unaudited Q3 2025 revenue of $8.1 million, representing a 91% increase over Q3 2024.
• Significant U.S. new patient growth of approximately 160% year-over-year.
• Achieved record quarterly new patient starts in Q3 2025, with September 2025 being the highest monthly new patient starts in company history.
• Increased investment in direct-to-consumer (DTC) marketing is accelerating awareness and driving momentum for Eversense 365.
• Bringing the full sales and marketing organization in-house is expected to drive topline revenue and exceed patient expectations.

Negatives

• The reverse stock split, while approved, is often perceived negatively by investors as it can signal underlying issues or an attempt to meet listing requirements.
• The financial results are preliminary and unaudited, meaning they are subject to change upon finalization.

Risks

• Uncertainties related to the previously announced decision to transition the commercialization of Eversense 365 from Ascensia to Senseonics.
• Inherent uncertainties in the current reliance on the commercialization efforts and investment of Ascensia and its commercial initiatives.
• Uncertainties in prescriber and patient decisions and responses to new technology or initiatives.
• Uncertainties in insurer, regulatory, and administrative processes and decisions.
• Inherent uncertainties in the development and registration of new technology.
• Uncertainties in the development of and competition in the overall Continuous Glucose Monitoring (CGM) market.
• The risk that the share price resulting from a reverse stock split may not attract institutional or other investors, may not satisfy the investing guidelines of these investors, or otherwise may not result in increased investor interest in Senseonics stock or improved trading liquidity in the company's stock.

Future Outlook

The company anticipates continued momentum for Eversense 365, driven by ongoing investments in direct-to-consumer marketing and the recent decision to bring the full sales and marketing organization in-house, which is expected to drive topline revenue and exceed patient expectations.

Management Comments

• "I am excited by the team's strong performance this quarter, which is a direct result of the increasing enthusiasm for Eversense 365, the world's first and only year-long CGM."
• "The ongoing investments we are making in our DTC marketing campaigns are accelerating awareness with patients and clinicians leading to the continued momentum behind Eversense."
• "This is what encouraged us to bring the full sales and marketing organization in-house, giving us increased confidence in our ability to drive topline revenue and exceed patient expectations."

Industry Context

Senseonics operates in the rapidly evolving continuous glucose monitoring (CGM) market, a segment of medical technology focused on diabetes management. The company's Eversense 365, a year-long implantable CGM, differentiates it from competitors like Dexcom and Abbott, which primarily offer shorter-term wearables. Increased investment in direct-to-consumer marketing and bringing sales in-house reflects a common strategy in competitive medical device markets to gain direct patient and clinician engagement.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a 1-for-20 reverse stock split, reducing the number of shares held but proportionally increasing the price per share. Fractional shares will be cashed out. The split aims to improve stock attractiveness and liquidity.
• Patients: Benefit from increased awareness and access to Eversense 365 due to accelerated direct-to-consumer marketing and an in-house sales/marketing team.
• Employees: The decision to bring sales and marketing in-house may impact existing roles or create new opportunities within Senseonics.

Next Steps

• The reverse stock split is anticipated to become effective at 5:00 p.m. ET on October 17, 2025.
• Common stock will begin trading on a post-split basis at market open on October 20, 2025.
• Stockholders of record will receive information from Computershare Trust Company, N.A. regarding their stock ownership following the Reverse Stock Split and cash in lieu of fractional share payments, if applicable.
• Continue investments in direct-to-consumer marketing campaigns to accelerate awareness and momentum for Eversense.
• Drive topline revenue and exceed patient expectations with the newly in-house sales and marketing organization.

Key Dates

Recommendation

While the company demonstrated strong preliminary revenue growth and significant patient acquisition, indicating positive operational momentum for its Eversense CGM system, the simultaneous announcement of a 1-for-20 reverse stock split introduces a notable element of caution. Reverse splits, while sometimes necessary for listing compliance or to attract institutional investors, can also be perceived negatively by the market and may not guarantee sustained stock price improvement or increased investor interest. Investors should hold to observe the market's reaction to the reverse split and monitor the company's ability to sustain its growth trajectory and manage the commercialization transition effectively.

Keywords

Senseonics, SENS, Continuous Glucose Monitoring, CGM, Eversense, Diabetes, Medical Technology, Reverse Stock Split, Q3 2025 Revenue, Patient Growth, Financial Results